These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 32366856)

  • 1. anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells.
    Liu S; Qin T; Liu Z; Wang J; Jia Y; Feng Y; Gao Y; Li K
    Cell Death Dis; 2020 May; 11(5):309. PubMed ID: 32366856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer.
    Yuan M; Zhai Y; Men Y; Zhao M; Sun X; Ma Z; Bao Y; Yang X; Sun S; Liu Y; Zhang W; Hui Z
    Oxid Med Cell Longev; 2022; 2022():5479491. PubMed ID: 35154567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anlotinib enhanced CD8
    Luo J; Cheng K; Ji X; Gao C; Zhu R; Chen J; Xue W; Huang Q; Xu Q
    Cancer Lett; 2024 Jun; 591():216892. PubMed ID: 38621459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decursin promotes HIF-1α proteasomal degradation and immune responses in hypoxic tumour microenvironment.
    Ge Y; Yoon SH; Jang H; Jeong JH; Lee YM
    Phytomedicine; 2020 Nov; 78():153318. PubMed ID: 32896707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
    Shima T; Shimoda M; Shigenobu T; Ohtsuka T; Nishimura T; Emoto K; Hayashi Y; Iwasaki T; Abe T; Asamura H; Kanai Y
    Cancer Sci; 2020 Feb; 111(2):727-738. PubMed ID: 31821665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-independent acquired resistance to PD-L1 antibody initiated by PD-L1 upregulation via PI3K/AKT signaling can be reversed by anlotinib.
    Gao Y; Feng Y; Liu S; Zhang Y; Wang J; Qin T; Chen P; Li K
    Cancer Med; 2023 Jul; 12(14):15337-15349. PubMed ID: 37350549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anlotinib may enhance the efficacy of anti-PD1 therapy by inhibiting the AKT pathway and promoting the apoptosis of CAFs in lung adenocarcinoma.
    Tang H; You T; Ge H; Gao J; Wang Y; Bai C; Sun Z; Han Q; Zhao RC
    Int Immunopharmacol; 2024 May; 133():112053. PubMed ID: 38615380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expression of C-MYC in gastric adenocarcinoma is associated with PD-L1 and FOXP3 expression: C-MYC overexpression is a good prognostic factor.
    Won KY; Kim GY; Kim HK; Song MJ; Choi SI; Bae GE; Lim SJ
    Pathol Res Pract; 2019 Nov; 215(11):152639. PubMed ID: 31582185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour immune microenvironment in primary and metastatic papillary renal cell carcinoma.
    Eich ML; Chaux A; Mendoza Rodriguez MA; Guner G; Taheri D; Rodriguez Pena MDC; Sharma R; Allaf ME; Netto GJ
    Histopathology; 2020 Feb; 76(3):423-432. PubMed ID: 31494951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 Regulates Inflammation in LPS-Induced Lung Epithelial Cells and Vascular Endothelial Cells by Interacting with the HIF-1α Signaling Pathway.
    Zhao S; Gao J; Li J; Wang S; Yuan C; Liu Q
    Inflammation; 2021 Oct; 44(5):1969-1981. PubMed ID: 34014492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer.
    Liu L; Mo M; Chen X; Chao D; Zhang Y; Chen X; Wang Y; Zhang N; He N; Yuan X; Chen H; Yang J
    J Exp Clin Cancer Res; 2023 Apr; 42(1):85. PubMed ID: 37055842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.
    Spranger S; Spaapen RM; Zha Y; Williams J; Meng Y; Ha TT; Gajewski TF
    Sci Transl Med; 2013 Aug; 5(200):200ra116. PubMed ID: 23986400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
    Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
    Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer cells promote CD169
    Jing W; Guo X; Wang G; Bi Y; Han L; Zhu Q; Qiu C; Tanaka M; Zhao Y
    Int Immunopharmacol; 2020 Jan; 78():106012. PubMed ID: 31865052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers.
    Sun Z; Nyberg R; Wu Y; Bernard B; Redmond WL
    PLoS One; 2021; 16(2):e0247238. PubMed ID: 33596250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer.
    Yang Y; Li L; Jiang Z; Wang B; Pan Z
    Cancer Immunol Immunother; 2020 Dec; 69(12):2523-2532. PubMed ID: 32577817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma.
    Thapa B; Salcedo A; Lin X; Walkiewicz M; Murone C; Ameratunga M; Asadi K; Deb S; Barnett SA; Knight S; Mitchell P; Watkins DN; Boutros PC; John T
    J Thorac Oncol; 2017 May; 12(5):850-859. PubMed ID: 28257959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.
    Imai D; Yoshizumi T; Okano S; Itoh S; Ikegami T; Harada N; Aishima S; Oda Y; Maehara Y
    J Surg Res; 2019 Aug; 240():115-123. PubMed ID: 30927618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.